WO1998022588A3 - An improved method for the production and purification of adenoviral vectors - Google Patents
An improved method for the production and purification of adenoviral vectors Download PDFInfo
- Publication number
- WO1998022588A3 WO1998022588A3 PCT/US1997/021504 US9721504W WO9822588A3 WO 1998022588 A3 WO1998022588 A3 WO 1998022588A3 US 9721504 W US9721504 W US 9721504W WO 9822588 A3 WO9822588 A3 WO 9822588A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- yields
- production
- purification
- serum
- cell culture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10045—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
- C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
- C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
- C12N2810/6018—Adenoviridae
Abstract
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU53617/98A AU732703B2 (en) | 1996-11-20 | 1997-11-20 | An improved method for the production and purification of adenoviral vectors |
CA2272820A CA2272820C (en) | 1996-11-20 | 1997-11-20 | An improved method for the production and purification of adenoviral vectors |
BR9713368-0A BR9713368A (en) | 1996-11-20 | 1997-11-20 | Improved process for the production and purification of adenoviral vectors |
DE69737107T DE69737107T2 (en) | 1996-11-20 | 1997-11-20 | AN IMPROVED PROCESS FOR THE PRODUCTION AND CLEANING OF ADENOVIRAL VECTORS |
EP97950677A EP0968284B1 (en) | 1996-11-20 | 1997-11-20 | An improved method for the production and purification of adenoviral vectors |
JP52396598A JP4492826B2 (en) | 1996-11-20 | 1997-11-20 | Improved method for production and purification of adenoviral vectors |
CN971812543A CN1244215B (en) | 1996-11-20 | 1997-11-20 | Improved method for the production and purification of adenoviral vectors |
NO992389A NO992389L (en) | 1996-11-20 | 1999-05-19 | Improved method of preparation and purification of adenoviral vectors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3132996P | 1996-11-20 | 1996-11-20 | |
US60/031,329 | 1996-11-20 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO1998022588A2 WO1998022588A2 (en) | 1998-05-28 |
WO1998022588A3 true WO1998022588A3 (en) | 1998-10-15 |
WO1998022588A9 WO1998022588A9 (en) | 1998-12-23 |
Family
ID=21858843
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/021504 WO1998022588A2 (en) | 1996-11-20 | 1997-11-20 | An improved method for the production and purification of adenoviral vectors |
Country Status (15)
Country | Link |
---|---|
US (7) | US6194191B1 (en) |
EP (3) | EP1760151B1 (en) |
JP (1) | JP4492826B2 (en) |
KR (1) | KR100503701B1 (en) |
CN (1) | CN1244215B (en) |
AT (2) | ATE348155T1 (en) |
AU (1) | AU732703B2 (en) |
BR (1) | BR9713368A (en) |
CA (1) | CA2272820C (en) |
DE (1) | DE69737107T2 (en) |
ES (2) | ES2278399T3 (en) |
HK (1) | HK1107116A1 (en) |
NO (1) | NO992389L (en) |
NZ (1) | NZ335947A (en) |
WO (1) | WO1998022588A2 (en) |
Families Citing this family (253)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008298A1 (en) * | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
US20020088014A1 (en) * | 1996-05-31 | 2002-07-04 | Xiangming Fang | Minimal adenovirus mediated recombinant vaccine |
BR9710030A (en) | 1996-07-01 | 1999-08-10 | Rhone Poulenc Rorer Sa | Process of production of recombinant adenoviruses process of purification of recombinant adenoviruses from a biological medium purified viral preparation pharmaceutical composition and use of iodixanol-5,5 '- [(2-Hydroxypropyl-1,3-Propanottl) -Bis [N, N'-Bis (2,3-Didroxypropyl-2,4,6-Triodo-1,3-Benzenocarboxamide] |
US7732129B1 (en) * | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
ES2278399T3 (en) * | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. |
US6544769B1 (en) | 1996-12-13 | 2003-04-08 | Schering Corporation | Compostions comprising viruses and methods for concentrating virus preparations |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
US6995006B2 (en) * | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
NZ504214A (en) * | 1997-10-24 | 2003-06-30 | Invitrogen Corp | Recombination cloning using nucleic acids having recombination sites |
US7705602B2 (en) * | 1997-11-03 | 2010-04-27 | Midtronics, Inc. | Automotive vehicle electrical system diagnostic device |
US20040204381A1 (en) * | 1997-11-12 | 2004-10-14 | Moskal Joseph R | Detection and treatment of glyco-enzyme-related disease |
US6899870B1 (en) * | 1998-03-11 | 2005-05-31 | Board Of Regents, The University Of Texas System | Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery |
EP1073721B1 (en) * | 1998-04-22 | 2005-08-31 | Genvec, Inc. | Efficient purification of adenovirus |
US6416992B1 (en) * | 1998-10-13 | 2002-07-09 | Avigen, Inc. | Compositions and methods for producing recombinant adeno-associated virus |
US7691370B2 (en) * | 1998-10-15 | 2010-04-06 | Canji, Inc. | Selectivity replicating viral vector |
WO2000029024A1 (en) * | 1998-11-16 | 2000-05-25 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US7148035B1 (en) * | 1998-11-18 | 2006-12-12 | Oxford Biomedica (Uk) Limited | Polypeptide |
US6210922B1 (en) * | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
FR2788064B1 (en) * | 1998-12-31 | 2003-01-31 | Aventis Pharma Sa | METHOD FOR SEPARATING VIRAL PARTICLES |
EP1141249A1 (en) | 1998-12-31 | 2001-10-10 | Aventis Pharma S.A. | Method for separating viral particles |
US7264958B1 (en) | 1999-02-22 | 2007-09-04 | Transgene, S.A. | Method for obtaining a purified viral preparation |
US6795585B1 (en) | 1999-07-16 | 2004-09-21 | Eastman Kodak Company | Representing digital images in a plurality of image processing states |
JP2003518380A (en) * | 1999-12-29 | 2003-06-10 | ジェンザイム・コーポレイション | Methods of using filter aids to separate viral vectors from nucleic acids and other cellular contaminants |
US6168941B1 (en) * | 2000-04-07 | 2001-01-02 | Genvec, Inc. | Method of producing adenoviral vector stocks |
EP1280409A4 (en) * | 2000-04-28 | 2004-05-19 | Zengen Inc | A gene therapy system and method using alpha-msh and its derivatives |
US6783939B2 (en) * | 2000-07-07 | 2004-08-31 | Alphavax, Inc. | Alphavirus vectors and virosomes with modified HIV genes for use in vaccines |
TWI289158B (en) * | 2000-08-10 | 2007-11-01 | Oncolytics Biotech Inc | Method of producing infectious reovirus |
US7198924B2 (en) | 2000-12-11 | 2007-04-03 | Invitrogen Corporation | Methods and compositions for synthesis of nucleic acid molecules using multiple recognition sites |
US20020064860A1 (en) * | 2000-11-29 | 2002-05-30 | Schering Corporation | Method for purifying adenoviruses |
MXPA03007535A (en) * | 2001-03-16 | 2003-12-11 | Oncolytics Biotech Inc | Method of extracting virus from cell culture. |
US20040146590A1 (en) | 2001-03-22 | 2004-07-29 | Iadarola Michael J | Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin |
NZ528462A (en) * | 2001-03-27 | 2005-11-25 | Vertex Pharma | Compositions and methods useful for HCV infection |
EP1427835B1 (en) | 2001-08-08 | 2016-01-20 | The Trustees of the University of Pennsylvania | Method for purification of viral vectors having proteins which bind sialic acid |
US20040253210A1 (en) * | 2001-08-30 | 2004-12-16 | Marjorie Robert-Guroff | Adenovirus type7 vectors |
WO2003023026A1 (en) * | 2001-09-06 | 2003-03-20 | Alphavax, Inc. | Alphavirus replicon vector systems |
WO2003039459A2 (en) * | 2001-11-05 | 2003-05-15 | Genvec, Inc. | Viral vector production methods and compositions |
EP1407006B9 (en) * | 2001-12-20 | 2006-10-18 | Bavarian Nordic A/S | Method for the recovery and purification of poxviruses from infected cells |
KR100451308B1 (en) * | 2001-12-28 | 2004-10-06 | 선바이오(주) | A virus removal process in the purification of biologically active molecules |
WO2003068804A2 (en) * | 2002-02-14 | 2003-08-21 | Novavax, Inc. | Novel insect cell line |
AU2003213072A1 (en) * | 2002-02-20 | 2003-09-09 | Merck And Co., Inc. | Method of determining adenovirus particle concentration |
US20030175688A1 (en) * | 2002-03-15 | 2003-09-18 | Rukmini Pennathur-Das | Method for the purification and production of oncolytic adenoviruses |
US20030186832A1 (en) * | 2002-03-15 | 2003-10-02 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Isotropic liquid detergents with improved anti-redeposition |
US20030180936A1 (en) * | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
JP2005521417A (en) * | 2002-03-29 | 2005-07-21 | メルク エンド カムパニー インコーポレーテッド | Large-scale production method of adenovirus and adenovirus seed stock |
EP1501921B2 (en) * | 2002-04-30 | 2012-07-25 | Oncolytics Biotech Inc. | Improved viral purification methods |
ES2357366T3 (en) * | 2002-05-14 | 2011-04-25 | MERCK SHARP & DOHME CORP. | ADENOVIRUS PURIFICATION PROCEDURES. |
US20030224354A1 (en) * | 2002-05-30 | 2003-12-04 | Introgen Therapeutics Inc. | Quantifying viral particles with intrinsic fluorescence |
EP1371723A1 (en) * | 2002-06-12 | 2003-12-17 | Procorde GmbH | Process for preparing an adenovirus-containing preparation |
WO2004009768A2 (en) * | 2002-07-18 | 2004-01-29 | Invitrogen Corporation | Viral vectors containing recombination sites |
US20040106184A1 (en) * | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
KR20110050745A (en) * | 2002-10-03 | 2011-05-16 | 탈자진 인코포레이티드 | Vasculostatic agents and methods of use thereof |
AU2003298594A1 (en) * | 2002-11-01 | 2004-06-07 | Promega Corporation | Cell lysis compositions, methods of use, apparatus, and kit |
JP4991108B2 (en) | 2002-12-13 | 2012-08-01 | アルファバックス,インコーポレイティド | Multi-antigenic alphavirus replicon particles and methods |
CA2509979C (en) * | 2002-12-13 | 2013-02-26 | Alphavax, Inc. | Alphavirus particles and methods for preparation |
EP2181704B1 (en) | 2002-12-30 | 2015-05-06 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
EP1594433B8 (en) | 2003-01-14 | 2016-12-21 | Dana-Farber Cancer Institute, Inc. | Cancer therapy sensitizer |
JP5016305B2 (en) * | 2003-03-20 | 2012-09-05 | アルファヴァックス,インコーポレイテッド | Improved alphavirus replicon and helper constructs |
ES2290705T3 (en) * | 2003-05-01 | 2008-02-16 | Dsm Ip Assets B.V. | PROCESS FOR THE PRODUCTION OF BIOLOGICAL SUBSTANCES BY CULTURE PERFUSION OF SUSPENDED ANIMAL CELLS. |
US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
CA2529053A1 (en) * | 2003-06-18 | 2004-12-29 | Onyx Pharmaceuticals, Inc. | Method for purifying virus |
ATE432285T1 (en) * | 2003-07-11 | 2009-06-15 | Alphavax Inc | CYTOMEGALOVIRUS VACCINES BASED ON ALPHAVIRUS |
CA2531773A1 (en) | 2003-07-21 | 2005-02-17 | Transgene S.A. | Novel multifunctional cytokines |
EP1697534B1 (en) | 2003-12-01 | 2010-06-02 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
EP1697505A1 (en) * | 2003-12-23 | 2006-09-06 | Schering Corporation | Methods for producing a549 cell lines stable in serum-free medium suspension culture |
ES2329607T3 (en) * | 2004-02-23 | 2009-11-27 | Crucell Holland B.V. | VIRUS PURIFICATION METHODS |
CN100333797C (en) * | 2005-01-26 | 2007-08-29 | 彭朝晖 | Use of tumor treating of recombinant adenoviral P53 products |
AU2005231507B2 (en) * | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
DK1751289T3 (en) * | 2004-05-18 | 2009-05-11 | Alphavax Inc | TC-83-derived alphavirus vectors, particles and methods |
EP4170024A1 (en) * | 2004-06-01 | 2023-04-26 | Genzyme Corporation | Compositions and methods to prevent aav vector aggregation |
US20050287616A1 (en) * | 2004-06-29 | 2005-12-29 | Gross Adam F | Method of assaying denaturation of proteins |
NZ588896A (en) | 2004-08-25 | 2012-05-25 | Targegen Inc | Heterocyclic compounds and methods of use |
DE202004014949U1 (en) * | 2004-09-25 | 2004-11-18 | Techno-Grafica Gmbh | Apparatus for heat treating a coating of flat offset printing plates |
DE102004049290A1 (en) * | 2004-10-09 | 2006-04-20 | Bayer Healthcare Ag | Process for the preparation of virus material |
US7901921B2 (en) * | 2004-10-22 | 2011-03-08 | Oncolytics Biotech Inc. | Viral purification methods |
CN101080488A (en) * | 2004-11-03 | 2007-11-28 | 因特罗根治疗公司 | Novel method for the production and purification of adenoviral vectors |
CN100497640C (en) * | 2004-11-26 | 2009-06-10 | 中国人民解放军军事医学科学院生物工程研究所 | High-efficient production of recombinant adenovirus carrier |
US20060166364A1 (en) * | 2004-12-22 | 2006-07-27 | Introgen, Inc. | Use of flexible bag containers for viral production |
ES2382557T3 (en) * | 2004-12-23 | 2012-06-11 | Medimmune, Llc | MDCK non-tumorigenic cell line to spread virus |
US20060205080A1 (en) * | 2005-03-01 | 2006-09-14 | David Frey | Formulations for therapeutic viruses having enhanced storage stability |
EA015584B1 (en) | 2005-03-23 | 2011-10-31 | Генмаб А/С | Antibody to human cd38 and use thereof |
CA2602944C (en) * | 2005-04-11 | 2015-08-11 | Crucell Holland B.V. | Virus purification using ultrafiltration |
US20060263415A1 (en) * | 2005-05-05 | 2006-11-23 | Sensient Flavors Inc. | Production of beta-glucans and mannans |
JP2008543775A (en) * | 2005-06-08 | 2008-12-04 | ターゲジェン インコーポレーティッド | Methods and compositions for treating ocular disorders |
WO2007005885A2 (en) * | 2005-07-05 | 2007-01-11 | David Nance | Energy recovery within a fluid distribution network using geographical information |
MY167260A (en) * | 2005-11-01 | 2018-08-14 | Targegen Inc | Bi-aryl meta-pyrimidine inhibitors of kinases |
US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
PL2005185T3 (en) * | 2006-03-22 | 2011-05-31 | Viral Logic Systems Tech Corp | Methods for identifying polypeptide targets |
WO2007127366A2 (en) * | 2006-04-25 | 2007-11-08 | Targegen, Inc. | Kinase inhibitors and methods of use thereof |
ES2473275T3 (en) * | 2006-09-15 | 2014-07-04 | Medimmune, Llc | MDCK cell lines that support viral growth up to high titers and bioreactor process that uses them. |
PL2118292T3 (en) | 2007-01-30 | 2011-12-30 | Transgene Sa | Papillomavirus e2 polypeptide used for vaccination |
US20080299624A1 (en) * | 2007-06-01 | 2008-12-04 | Edward Heslop | Continuous fermentation apparatus and method |
DK2183368T3 (en) | 2007-06-21 | 2016-09-05 | Alphavax Inc | PROMOTER-FREE CASES FOR EXPRESSION OF ALPHAVIRUS STRUCTURE PROTEINS |
EP2207874B1 (en) * | 2007-10-08 | 2014-12-03 | Intrexon Corporation | Engineered dendritic cells and uses for the treatment of cancer |
WO2009058564A2 (en) | 2007-11-01 | 2009-05-07 | Maxygen, Inc. | Immunosuppressive polypeptides and nucleic acids |
US20090253184A1 (en) * | 2008-01-23 | 2009-10-08 | Introgen Therapeutics, Inc. | Compositions and methods related to an adenoviral trans-complementing cell line |
CA2723726C (en) * | 2008-05-13 | 2017-09-12 | Michael M. Becker | Inactivatable target capture oligomers for use in the selective hybridization and capture of target nucleic acid sequences |
PL3192874T3 (en) * | 2008-06-18 | 2020-06-29 | Oxford Biomedica (Uk) Limited | Virus purification |
AU2009296628B2 (en) | 2008-09-24 | 2015-01-15 | Medimmune, Llc | Methods for purification of viruses |
RU2015103990A (en) * | 2008-09-24 | 2015-10-27 | Медиммун, Ллк | METHODS OF CULTIVATION OF CELLS, REPRODUCTION AND CLEANING OF VIRUSES |
CA2742474C (en) | 2008-11-03 | 2016-05-31 | Crucell Holland B.V. | Method for the production of adenoviral vectors |
WO2010062757A1 (en) * | 2008-11-03 | 2010-06-03 | Ligocyte Pharmaceuticals, Inc. | Improved methods for isolating enveloped virus-based vlps free of infectious agents |
WO2010136979A2 (en) * | 2009-05-26 | 2010-12-02 | Leviathan Energy Hydroelectric Ltd. | Hydroelectric in-pipe turbine uses |
CN103335945A (en) * | 2009-07-07 | 2013-10-02 | 索尼公司 | Microfluidic device |
MX2012001592A (en) | 2009-08-07 | 2012-05-22 | Transgene Sa | Composition for treating hbv infection. |
EA028623B1 (en) | 2009-10-15 | 2017-12-29 | Янссен Вэксинс Энд Превеншн Б.В. | Method for the purification of adenovirus particles |
BR112012008507B8 (en) | 2009-10-15 | 2021-05-25 | Crucell Holland Bv | method for purifying adenovirus particles from a cell suspension |
DK2521776T3 (en) | 2010-01-05 | 2017-02-13 | Vascular Biogenics Ltd | METHODS FOR USING A SPECIFIC ANTI-ANGIOGENT ADENOVIRAL AGENT |
WO2011083466A1 (en) | 2010-01-05 | 2011-07-14 | Vascular Biogenics Ltd. | Compositions and methods for treating glioblastoma gbm |
WO2011086509A1 (en) * | 2010-01-12 | 2011-07-21 | Vascular Biogenics Ltd. | Methods of producing adenovirus vectors and viral preparations generated thereby |
CN102762721B (en) | 2010-02-15 | 2015-03-11 | 克鲁塞尔荷兰公司 | Method for the production of Ad26 adenoviral vectors |
SG184833A1 (en) * | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
WO2012019354A1 (en) | 2010-08-12 | 2012-02-16 | Yisheng Biopharma Holdings Ltd. | Method for reducing dna impurities in viral compositions |
CA2808556A1 (en) | 2010-09-20 | 2012-03-29 | Crucell Holland B.V. | Therapeutic vaccination against active tuberculosis |
MX354752B (en) | 2010-09-27 | 2018-03-20 | Janssen Vaccines & Prevention Bv | Heterologous prime boost vaccination regimen against malaria. |
US8892184B2 (en) | 2010-10-18 | 2014-11-18 | Siemens Medical Solutions Usa, Inc. | Systems and methods for reducing interference in a dual modality imaging system |
CA2816957A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
EP2461162A1 (en) | 2010-12-03 | 2012-06-06 | Texcell, . | Method for determining the titre of viruses by using infectious standards |
CN103476928B (en) | 2010-12-09 | 2017-03-29 | 巴斯德研究所 | For obtaining the method based on MGMT of high yield expression of recombinant proteins |
TWI575070B (en) | 2011-07-12 | 2017-03-21 | 傳斯堅公司 | Hbv polymerase mutants |
TW201321016A (en) | 2011-09-29 | 2013-06-01 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis C virus infection |
WO2013045658A1 (en) | 2011-09-29 | 2013-04-04 | Transgene Sa | Immunotherapy composition and regimen for treating hepatitis c virus infection |
US20130122038A1 (en) | 2011-11-14 | 2013-05-16 | The United States Of America As Represented By The Secretary Of The Department | Heterologous prime-boost immunization using measles virus-based vaccines |
CN104379733B (en) | 2012-03-12 | 2016-01-20 | 克鲁塞尔荷兰公司 | Tool changes the recombinant adenovirus group of end |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
WO2013139911A1 (en) | 2012-03-22 | 2013-09-26 | Crucell Holland B.V. | Vaccine against rsv |
US9125870B2 (en) | 2012-03-22 | 2015-09-08 | Crucell Holland B.V. | Vaccine against RSV |
ES2740004T3 (en) * | 2012-07-26 | 2020-02-05 | Flash Therapeutics | Method to detect or measure the impact of a viral vector composition on eukaryotic cells and their biomarkers used |
JP6430949B2 (en) | 2012-10-23 | 2018-11-28 | エモリー ユニバーシティ | Conjugates, compositions, and related methods of GM-CSF and IL-4 |
EA039803B1 (en) | 2013-04-25 | 2022-03-15 | Янссен Вэксинс Энд Превеншн Б.В. | Stabilized soluble prefusion rsv f polypeptides |
WO2014179108A1 (en) | 2013-05-03 | 2014-11-06 | Honeywell International Inc. | Lead frame construct for lead-free solder connections |
SG11201510216RA (en) | 2013-06-17 | 2016-01-28 | Crucell Holland Bv | Stabilized soluble pre-fusion rsv f polypeptides |
US9956166B2 (en) | 2013-09-18 | 2018-05-01 | Sorrento Therapeutics, Inc. | Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin |
CN105658806A (en) * | 2013-10-30 | 2016-06-08 | 默克专利股份公司 | Method for isolating microorganisms from complex sample |
JP2017509489A (en) | 2014-02-20 | 2017-04-06 | ハネウェル・インターナショナル・インコーポレーテッド | Lead-free solder composition |
JP6783143B2 (en) | 2014-03-25 | 2020-11-11 | テルモ ビーシーティー、インコーポレーテッド | Passive replenishment of medium |
EA201691696A1 (en) | 2014-04-25 | 2017-03-31 | Шир Хьюман Дженетик Терапис, Инк. | METHODS OF CLEANING MATRIX RNA |
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
CN105316296A (en) * | 2014-06-13 | 2016-02-10 | 亚宝药业太原制药有限公司 | Method of purifying adenovirus granules |
WO2016040441A1 (en) | 2014-09-09 | 2016-03-17 | Unum Therapeutics | Chimeric receptors and uses thereof in immune therapy |
GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
CN112553229A (en) | 2014-11-05 | 2021-03-26 | 沃雅戈治疗公司 | AADC polynucleotides for treating Parkinson's disease |
CN107207556B (en) | 2014-11-14 | 2020-12-08 | 沃雅戈治疗公司 | Regulatory polynucleotides |
RU2020108189A (en) | 2014-11-14 | 2020-03-11 | Вояджер Терапьютикс, Инк. | COMPOSITIONS AND METHODS OF TREATMENT OF LATERAL AMYOTROPHIC SCLEROSIS (ALS) |
US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
CN107428799A (en) | 2015-01-13 | 2017-12-01 | 阿尔法韦士曼公司 | Purify adeno-associated virus (AAV) and/or the method and its gradient and flow type buffer solution of recombinant adeno-associated virus (rAAV) |
EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
US10570417B2 (en) | 2015-04-14 | 2020-02-25 | Janssen Vaccines & Prevention B.V. | Recombinant adenovirus expressing two transgenes with a bidirectional promoter |
WO2017004592A1 (en) | 2015-07-02 | 2017-01-05 | Terumo Bct, Inc. | Cell growth with mechanical stimuli |
WO2017005848A1 (en) | 2015-07-07 | 2017-01-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
US10456462B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Preventions B.V. | Vaccine against RSV |
US9663766B2 (en) | 2015-07-24 | 2017-05-30 | Bio-Rad Laboratories, Inc. | Methods for purifying adenovirus vectors |
MX2018004546A (en) | 2015-10-16 | 2019-04-15 | Univ Columbia | Compositions and methods for inhibition of lineage specific antigens. |
WO2017075335A1 (en) | 2015-10-28 | 2017-05-04 | Voyager Therapeutics, Inc. | Regulatable expression using adeno-associated virus (aav) |
CN109069612A (en) | 2016-04-05 | 2018-12-21 | 扬森疫苗与预防公司 | For the vaccine of RSV |
PL3439672T3 (en) | 2016-04-05 | 2021-06-14 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f protein for use in the prophylaxis of rsv infection |
KR102535013B1 (en) * | 2016-04-14 | 2023-05-22 | 트리젤 엘티디. | Fixed bed bioreactor with constant flow pump/tubing system |
KR20230022177A (en) * | 2016-04-14 | 2023-02-14 | 트리젤 엘티디. | Fixed-bed bioreactor with constant-flow pumpi tubing system |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US20190134190A1 (en) | 2016-05-04 | 2019-05-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
JP7066635B2 (en) | 2016-05-18 | 2022-05-13 | ボイジャー セラピューティクス インコーポレイテッド | Modulatory polynucleotide |
JP2019523644A (en) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F protein |
US11685883B2 (en) | 2016-06-07 | 2023-06-27 | Terumo Bct, Inc. | Methods and systems for coating a cell growth surface |
US11104874B2 (en) | 2016-06-07 | 2021-08-31 | Terumo Bct, Inc. | Coating a bioreactor |
EP3472327B1 (en) | 2016-06-20 | 2020-08-19 | Janssen Vaccines & Prevention B.V. | Potent and balanced bidirectional promoter |
WO2018011196A1 (en) | 2016-07-14 | 2018-01-18 | Janssen Vaccines & Prevention B.V. | Hpv vaccines |
WO2018044933A1 (en) | 2016-08-30 | 2018-03-08 | The Regents Of The University Of California | Methods for biomedical targeting and delivery and devices and systems for practicing the same |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
WO2018080573A1 (en) | 2016-10-28 | 2018-05-03 | Massachusetts Institute Of Technology | Crispr/cas global regulator screening platform |
CN108085301B (en) * | 2016-11-22 | 2021-10-26 | 贺道耀 | Method for extracting and purifying adeno-associated virus and adenovirus from host cell, and components and kit thereof |
US10294452B2 (en) | 2016-11-22 | 2019-05-21 | Dao-Yao He | Lysis, extraction and purification of adeno-associated virus and adenovirus from host cells |
WO2018106888A1 (en) * | 2016-12-08 | 2018-06-14 | Temple University-Of The Commonwealth System Of Higher Education | Small animal models for in vivo testing of polyomavirus therapeutics |
WO2018148246A1 (en) | 2017-02-07 | 2018-08-16 | Massachusetts Institute Of Technology | Methods and compositions for rna-guided genetic circuits |
EP3656841A1 (en) | 2017-03-31 | 2020-05-27 | Terumo BCT, Inc. | Cell expansion |
US11752181B2 (en) | 2017-05-05 | 2023-09-12 | Voyager Therapeutics, Inc. | Compositions and methods of treating Huntington's disease |
JP2020518258A (en) | 2017-05-05 | 2020-06-25 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Amyotrophic lateral sclerosis (ALS) treatment composition and method |
JP2020519663A (en) | 2017-05-17 | 2020-07-02 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against RSV infection |
JOP20190269A1 (en) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
CN111132626B (en) | 2017-07-17 | 2024-01-30 | 沃雅戈治疗公司 | Track array guidance system |
WO2019028306A2 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
CN107384873A (en) * | 2017-09-05 | 2017-11-24 | 成都汇宇生物技术有限公司 | The purification process of recombined adhenovirus |
SG11202001458SA (en) | 2017-09-15 | 2020-03-30 | Janssen Vaccines & Prevention Bv | Method for the safe induction of immunity against rsv |
WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
AU2018352236A1 (en) | 2017-10-16 | 2020-04-23 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
EP3707250A1 (en) * | 2017-11-08 | 2020-09-16 | Blue Sky Vaccines GmbH | So3 chromatography for use in a method for virus purification |
US20210010028A1 (en) | 2018-03-06 | 2021-01-14 | Voyager Therapeutics, Inc. | Insect cell manufactured partial self-complementary aav genomes |
CN112313331A (en) | 2018-04-27 | 2021-02-02 | 沃雅戈治疗公司 | Method for measuring efficacy of AADC viral vector |
TW202015742A (en) | 2018-05-15 | 2020-05-01 | 美商航海家醫療公司 | Compositions and methods for delivery of aav |
JP2021523914A (en) | 2018-05-15 | 2021-09-09 | ボイジャー セラピューティクス インコーポレイテッドVoyager Therapeutics,Inc. | Compositions and Methods for Treating Parkinson's Disease |
WO2019222441A1 (en) | 2018-05-16 | 2019-11-21 | Voyager Therapeutics, Inc. | Aav serotypes for brain specific payload delivery |
EP3793615A2 (en) | 2018-05-16 | 2021-03-24 | Voyager Therapeutics, Inc. | Directed evolution of aav to improve tropism for cns |
CA3103963A1 (en) | 2018-07-02 | 2020-01-09 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis and disorders associated with the spinal cord |
MX2021000810A (en) | 2018-07-24 | 2021-04-28 | Voyager Therapeutics Inc | Systems and methods for producing gene therapy formulations. |
BR112021003670A2 (en) | 2018-08-28 | 2021-05-18 | Vor Biopharma, Inc. | genetically modified hematopoietic stem cells and their uses |
EP3861010A1 (en) | 2018-10-02 | 2021-08-11 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
WO2020072849A1 (en) | 2018-10-04 | 2020-04-09 | Voyager Therapeutics, Inc. | Methods for measuring the titer and potency of viral vector particles |
US20210371470A1 (en) | 2018-10-12 | 2021-12-02 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP3876953A4 (en) * | 2018-12-11 | 2022-10-19 | ERBI Biosystems, Inc. | Methods of manufacturing cell based products using small volume perfusion processes |
SG11202107645RA (en) | 2019-01-18 | 2021-08-30 | Voyager Therapeutics Inc | Methods and systems for producing aav particles |
US11542526B2 (en) | 2019-02-21 | 2023-01-03 | Unleash Immuno Oncolytics, Inc. | Oncolytic adenoviral vector and methods of use |
CN110093455B (en) * | 2019-04-27 | 2020-03-17 | 中国医学科学院病原生物学研究所 | Respiratory virus detection method |
WO2020223274A1 (en) | 2019-04-29 | 2020-11-05 | Voyager Therapeutics, Inc. | SYSTEMS AND METHODS FOR PRODUCING BACULOVIRAL INFECTED INSECT CELLS (BIICs) IN BIOREACTORS |
EP3966227A1 (en) | 2019-05-07 | 2022-03-16 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
CN112175996A (en) * | 2019-07-05 | 2021-01-05 | 杭州荣泽生物科技有限公司 | Preparation method and application of gene therapy vector |
EP4010465A1 (en) | 2019-08-09 | 2022-06-15 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
TW202122582A (en) | 2019-08-26 | 2021-06-16 | 美商航海家醫療公司 | Controlled expression of viral proteins |
US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
US20210147779A1 (en) * | 2019-11-15 | 2021-05-20 | City Of Hope | System, device and method for production of bioproduct including high density cell respirator (hdcr) for intensified production of adeno-associated viruses (aav) and cell-based production |
CN110894494B (en) * | 2019-11-22 | 2022-09-27 | 广西梧州制药(集团)股份有限公司 | Method for large-scale high-density suspension culture of 293 cell high-yield adenovirus |
WO2021202651A1 (en) | 2020-04-01 | 2021-10-07 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
CA3180222A1 (en) | 2020-04-15 | 2021-10-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
GB202005732D0 (en) | 2020-04-20 | 2020-06-03 | Synpromics Ltd | Regulatory nucleic acid sequences |
CN116096734A (en) | 2020-05-13 | 2023-05-09 | 沃雅戈治疗公司 | Redirection of tropism of AAV capsids |
EP4192514A1 (en) | 2020-08-06 | 2023-06-14 | Voyager Therapeutics, Inc. | Cell culture medium for use in producing gene therapy products in bioreactors |
GB202013940D0 (en) | 2020-09-04 | 2020-10-21 | Synpromics Ltd | Regulatory nucleic acid sequences |
CN112226418B (en) * | 2020-09-25 | 2022-07-08 | 阜外华中心血管病医院 | Recombinant adeno-associated virus purification method |
EP4225382A2 (en) | 2020-10-07 | 2023-08-16 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 |
CN112293394B (en) * | 2020-10-30 | 2022-11-25 | 海南德安欣有害生物防治科技有限公司 | Mouse trapping device and method |
KR20230078805A (en) | 2020-11-02 | 2023-06-02 | 바이오마린 파머수티컬 인크. | Enrichment process of adeno-associated virus |
GB202019454D0 (en) * | 2020-12-10 | 2021-01-27 | Chancellor Masters And Scholars Of The Univ Of Oxford | Method for purifying virus |
WO2022187473A2 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2022187548A1 (en) | 2021-03-03 | 2022-09-09 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2023034989A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034990A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034994A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034997A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034980A1 (en) | 2021-09-03 | 2023-03-09 | Bomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023034996A1 (en) | 2021-09-03 | 2023-03-09 | Biomarin Pharmaceutical Inc. | Aav capsid compositions and methods for delivery |
WO2023044483A2 (en) | 2021-09-20 | 2023-03-23 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
CA3232833A1 (en) | 2021-09-27 | 2023-03-30 | Kathleen Mcginness | Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof |
WO2023081648A1 (en) | 2021-11-02 | 2023-05-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
WO2023091948A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2023111580A1 (en) | 2021-12-16 | 2023-06-22 | University Of Dundee | Targeted degradation of alpha-synuclein |
WO2023147374A2 (en) | 2022-01-25 | 2023-08-03 | Voyager Therapeutics, Inc. | Baculovirus expression system |
WO2023154693A1 (en) | 2022-02-08 | 2023-08-17 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
GB202201713D0 (en) | 2022-02-10 | 2022-03-30 | Univ Dundee | An affinity directed phosphatase system for targeted protein dephosphorylation |
CN115354033A (en) * | 2022-03-25 | 2022-11-18 | 上海碧博生物医药科技有限公司 | Cell lysis solution, cell lysis method and application of cell lysis method in AAV (adeno-associated virus) harvesting |
WO2023235791A1 (en) | 2022-06-02 | 2023-12-07 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024006741A1 (en) | 2022-06-28 | 2024-01-04 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024011112A1 (en) | 2022-07-06 | 2024-01-11 | Voyager Therapeutics, Inc. | Aav capsid variants and uses thereof |
WO2024040208A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof |
WO2024040207A1 (en) | 2022-08-19 | 2024-02-22 | Sotio Biotech Inc. | Genetically engineered natural killer (nk) cells with chimeric receptor polypeptides in combination with trans metabolism molecules and therapeutic uses thereof |
WO2024054983A1 (en) | 2022-09-08 | 2024-03-14 | Voyager Therapeutics, Inc. | Controlled expression of viral proteins |
WO2024059739A1 (en) | 2022-09-15 | 2024-03-21 | Voyager Therapeutics, Inc. | Tau binding compounds |
WO2024064856A1 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of cardiomyopathy with aav gene therapy vectors |
WO2024064863A2 (en) | 2022-09-22 | 2024-03-28 | Biomarin Pharmaceutical Inc. | Treatment of arrhythmogenic cardiomyopathy with aav gene therapy vectors |
CN117551624A (en) * | 2024-01-11 | 2024-02-13 | 深圳源兴基因技术有限公司 | Method for efficiently recovering adenovirus based on serum-free suspension amplification |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996027677A2 (en) * | 1995-03-07 | 1996-09-12 | Canji, Inc. | Method of purification of recombinant viral vectors containing a therapeutic gene |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US789244A (en) * | 1902-10-01 | 1905-05-09 | Hans Thormeyer | Steam-turbine. |
US824544A (en) * | 1905-12-04 | 1906-06-26 | George Hossege | Pipe-hanger. |
US4222743A (en) | 1978-07-20 | 1980-09-16 | Wang Wei Kung | Method and apparatus for detecting biological particles by fluorescent stain |
US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
US4539020A (en) * | 1983-07-10 | 1985-09-03 | Kawasaki Steel Corporation | Methods for obtaining high-purity carbon monoxide |
JPS6147187A (en) | 1984-08-10 | 1986-03-07 | Chemo Sero Therapeut Res Inst | Method of purifying rabies virus |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5173418A (en) * | 1985-05-10 | 1992-12-22 | Benzon Pharma, A/S | Production in Escherichia coli of extracellular Serratia spp. hydrolases |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5106841A (en) * | 1986-05-13 | 1992-04-21 | Chai-Tech Corporation | Antiviral compositions and method for their use |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5591624A (en) * | 1988-03-21 | 1997-01-07 | Chiron Viagene, Inc. | Retroviral packaging cell lines |
JPH0761955B2 (en) | 1988-04-28 | 1995-07-05 | 国立予防衛生研究所長 | Lyophilized hepatitis A vaccine |
US5219752A (en) * | 1988-05-25 | 1993-06-15 | Teijin, Limited | Process for continuously culturing adherent animal cells |
DE59006065D1 (en) | 1989-01-16 | 1994-07-14 | Telefunken Fernseh & Rundfunk | Kompatibles frequenzmultiplex-fernsehsystem. |
EP0470982B1 (en) | 1989-05-01 | 1993-07-14 | BOHNENKAMP, Wolfram | Reflection fluorimeter |
WO1991009310A1 (en) | 1989-12-12 | 1991-06-27 | Lidak Pharmaceuticals | Free fatty acid determination |
IT1238231B (en) | 1989-12-18 | 1993-07-12 | Consiglio Nazionale Ricerche | USE OF IMMUNOMODULANTS AS SYNERGIC AGENTS OF CHEMOTHERAPY IN CANCER THERAPY |
US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
NO312681B1 (en) | 1990-08-24 | 2002-06-17 | Univ California | Process for the preparation of a pharmaceutical composition with suppressive action / activity |
US6410010B1 (en) | 1992-10-13 | 2002-06-25 | Board Of Regents, The University Of Texas System | Recombinant P53 adenovirus compositions |
IT1248075B (en) | 1991-06-18 | 1995-01-05 | Sclavo Spa | HEPATITIS A (HAV) VIRUS PURIFICATION PROCESS, PURIFIED VIRUS AND VACCINAL COMPOSITIONS THAT CONTAIN IT. |
DE69326967T2 (en) | 1992-01-17 | 2000-06-15 | Lakowicz Joseph R | Phase modulation energy transfer fluoroimmunoassay |
US5323008A (en) | 1992-03-23 | 1994-06-21 | Diatron Corporation | Fluorometer detection system |
AU673827B2 (en) | 1992-03-24 | 1996-11-28 | United Cancer Research Institute | Vaccine containing live virus for therapy of viral diseases and malignancies |
US5428011A (en) | 1992-06-16 | 1995-06-27 | Procyon Biopharma, Inc. | Pharmaceutical preparations for inhibiting tumours associated with prostate adenocarcinoma |
US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
WO1994002638A1 (en) * | 1992-07-17 | 1994-02-03 | Aprogenex, Inc. | Free radical scavengers useful for reducing autofluorescence in fixed cells |
CA2144848A1 (en) | 1992-09-18 | 1994-03-31 | H. Michael Shepard | Gene therapy by retroviral vector with tumor suppressive gene |
US5733721A (en) * | 1992-11-20 | 1998-03-31 | The Board Of Regents Of The University Of Oklahoma | Cell analysis method using quantitative fluorescence image analysis |
JP3246664B2 (en) | 1993-01-29 | 2002-01-15 | ニュー ブルンズウイック サイエンティフィック カンパニー インコーポレイテッド | Scaffold and method for culturing suspended cells and apparatus therefor |
US5604096A (en) * | 1993-03-04 | 1997-02-18 | Schaeffer; Warren I. | Fluorometric quantitation of mycoplasmas |
US5994314A (en) | 1993-04-07 | 1999-11-30 | Inhale Therapeutic Systems, Inc. | Compositions and methods for nucleic acid delivery to the lung |
EP0655091A1 (en) | 1993-05-06 | 1995-05-31 | Baxter Diagnostics Inc. | Human papillomavirus detection assay |
US5421339A (en) * | 1993-05-12 | 1995-06-06 | Board Of Regents, The University Of Texas System | Diagnosis of dysplasia using laser induced fluoroescence |
US6686200B1 (en) * | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
AU7971194A (en) | 1993-10-12 | 1995-05-04 | Chiron Corporation | Methods for preserving recombinant viruses |
TW442569B (en) * | 1993-10-25 | 2001-06-23 | Canji Inc | Recombinant adenoviral vector |
EP0738319A4 (en) * | 1994-01-12 | 2000-03-29 | Genetic Therapy Inc | Purification of retroviral vectors |
HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
US5498537A (en) * | 1994-03-09 | 1996-03-12 | Cellco, Inc. | Serum-free production of packaged viral vector |
WO1995025789A1 (en) * | 1994-03-22 | 1995-09-28 | The Immune Response Corporation | Highly efficient production and isolation of viral particles |
US5521083A (en) * | 1994-05-13 | 1996-05-28 | The Research Foundation Of State University Of New York Et Al. | Large granular lymphocyte leukemia associated virus |
AU3551195A (en) * | 1994-09-23 | 1996-04-09 | Somatix Therapy Corporation | Chimeric adenovirus for gene delivery |
US5552309A (en) | 1994-09-30 | 1996-09-03 | Indiana University Foundation | Use of polyols for improving the introduction of genetic material into cells |
US6348343B2 (en) * | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
US5707618A (en) * | 1995-03-24 | 1998-01-13 | Genzyme Corporation | Adenovirus vectors for gene therapy |
US5744304A (en) * | 1995-05-30 | 1998-04-28 | Board Of Regents, The University Of Texas System | Inflammation-induced expression of a recombinant gene |
WO1997005480A1 (en) * | 1995-07-27 | 1997-02-13 | Massachusetts Institute Of Technology | Separation and/or concentration of an analyte from a mixture using a two-phase aqueous micellar system |
KR19990036028A (en) * | 1995-08-01 | 1999-05-25 | 다니엘 케르니 | Industrial production method of Japanese encephalitis vaccine and vaccine by it |
WO1997008298A1 (en) * | 1995-08-30 | 1997-03-06 | Genzyme Corporation | Chromatographic purification of adenovirus and aav |
DK0863984T3 (en) | 1995-11-30 | 2006-08-28 | Univ Texas | Methods and Preparations for the Treatment of Cancer |
US5910434A (en) * | 1995-12-15 | 1999-06-08 | Systemix, Inc. | Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant |
US5789244A (en) | 1996-01-08 | 1998-08-04 | Canji, Inc. | Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems |
AR006240A1 (en) * | 1996-03-14 | 1999-08-11 | Fuller H B Licensing Financ | HOT MELTING ADHESIVE INCLUDING INTERPOLYMERS, NON-WOVEN ARTICLE THAT UNDERSTANDS IT, POLYMERIZATION PROCEDURE FOR PREPARATION AND BOX, CONTAINER, TRAY AND BOOK UNITED WITH SUCH ADHESIVE |
JPH09262099A (en) * | 1996-03-28 | 1997-10-07 | Aisin Seiki Co Ltd | Detection of nucleic acid with phosphate of fluorescein derivative |
BR9710030A (en) * | 1996-07-01 | 1999-08-10 | Rhone Poulenc Rorer Sa | Process of production of recombinant adenoviruses process of purification of recombinant adenoviruses from a biological medium purified viral preparation pharmaceutical composition and use of iodixanol-5,5 '- [(2-Hydroxypropyl-1,3-Propanottl) -Bis [N, N'-Bis (2,3-Didroxypropyl-2,4,6-Triodo-1,3-Benzenocarboxamide] |
ES2278399T3 (en) | 1996-11-20 | 2007-08-01 | Introgen Therapeutics, Inc. | IMPROVED METHOD FOR THE PRODUCTION AND PURIFICATION OF ADENOVIRAL VECTORS. |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
CA2274876A1 (en) | 1996-12-13 | 1998-06-18 | Schering Corporation | Method for purifying viruses |
US6168944B1 (en) | 1997-01-31 | 2001-01-02 | Schering Corporation | Methods for cultivating cells and propagating viruses |
ATE361668T1 (en) | 1997-02-18 | 2007-06-15 | Canji Inc | COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN NEOPLASM TREATMENT |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
US6130313A (en) | 1997-10-02 | 2000-10-10 | Clontech Laboratories, Inc. | Rapidly degrading GFP-fusion proteins |
KR100862169B1 (en) | 1998-02-17 | 2008-10-09 | 쉐링 코포레이션 | Compositions comprising viruses |
US5922576A (en) | 1998-02-27 | 1999-07-13 | The John Hopkins University | Simplified system for generating recombinant adenoviruses |
CA2322202C (en) | 1998-03-10 | 2010-11-30 | Large Scale Proteomics Corporation | Detection and characterization of microorganisms |
US6265151B1 (en) | 1998-03-27 | 2001-07-24 | Seroptix, Inc. | Apparatus and method for infectious disease detection |
EP1073721B1 (en) | 1998-04-22 | 2005-08-31 | Genvec, Inc. | Efficient purification of adenovirus |
US6171790B1 (en) | 1998-05-01 | 2001-01-09 | Incyte Pharmaceuticals, Inc. | Human protease associated proteins |
AU4188599A (en) | 1998-05-15 | 1999-12-06 | Geron Corporation | Method and apparatus for detecting hazardous agents |
JP3718430B2 (en) | 1998-06-30 | 2005-11-24 | ラミナ,インコーポレイテッド | Cell and tissue fixative compositions and methods of use |
AU5429399A (en) | 1998-08-08 | 2000-02-28 | Imperial Cancer Research Technology Limited | Fluorescent assay for biological systems |
US5965358A (en) * | 1998-08-26 | 1999-10-12 | Genvec, Inc. | Method for assessing the relative purity of viral gene transfer vector stocks |
US6689600B1 (en) | 1998-11-16 | 2004-02-10 | Introgen Therapeutics, Inc. | Formulation of adenovirus for gene therapy |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
EP1141249A1 (en) | 1998-12-31 | 2001-10-10 | Aventis Pharma S.A. | Method for separating viral particles |
US6316185B1 (en) * | 1999-09-29 | 2001-11-13 | Mountain View Pharmaceuticals, Inc. | Quantitation of viruses by light scattering |
JP2002054561A (en) * | 2000-08-08 | 2002-02-20 | Toyota Industries Corp | Control valve of variable displacement compressor, and variable displacement compressor |
US6447995B1 (en) | 2000-10-04 | 2002-09-10 | Genvec, Inc. | Utilizing intrinsic fluorescence to detect adenovirus |
DE10050114A1 (en) * | 2000-10-09 | 2002-04-25 | Wolf Gmbh Richard | Use of a gel mass |
US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
US20040229335A1 (en) * | 2003-05-15 | 2004-11-18 | Introgen Therapeutics, Inc. | Methods and compositions for the production of adenoviral vectors |
-
1997
- 1997-11-20 ES ES97950677T patent/ES2278399T3/en not_active Expired - Lifetime
- 1997-11-20 BR BR9713368-0A patent/BR9713368A/en not_active Application Discontinuation
- 1997-11-20 EP EP06025694A patent/EP1760151B1/en not_active Expired - Lifetime
- 1997-11-20 CN CN971812543A patent/CN1244215B/en not_active Expired - Lifetime
- 1997-11-20 WO PCT/US1997/021504 patent/WO1998022588A2/en active IP Right Grant
- 1997-11-20 AT AT97950677T patent/ATE348155T1/en active
- 1997-11-20 DE DE69737107T patent/DE69737107T2/en not_active Expired - Lifetime
- 1997-11-20 AT AT06025694T patent/ATE550429T1/en active
- 1997-11-20 US US08/975,519 patent/US6194191B1/en not_active Expired - Lifetime
- 1997-11-20 EP EP06012869A patent/EP1707631A3/en not_active Withdrawn
- 1997-11-20 KR KR10-1999-7004446A patent/KR100503701B1/en not_active IP Right Cessation
- 1997-11-20 NZ NZ335947A patent/NZ335947A/en not_active IP Right Cessation
- 1997-11-20 EP EP97950677A patent/EP0968284B1/en not_active Expired - Lifetime
- 1997-11-20 CA CA2272820A patent/CA2272820C/en not_active Expired - Lifetime
- 1997-11-20 AU AU53617/98A patent/AU732703B2/en not_active Expired
- 1997-11-20 JP JP52396598A patent/JP4492826B2/en not_active Expired - Lifetime
- 1997-11-20 ES ES06025694T patent/ES2383640T3/en not_active Expired - Lifetime
-
1999
- 1999-05-19 NO NO992389A patent/NO992389L/en not_active Application Discontinuation
-
2000
- 2000-04-24 US US09/556,570 patent/US6726907B1/en not_active Expired - Lifetime
-
2001
- 2001-12-27 US US10/033,491 patent/US20030008375A1/en not_active Abandoned
- 2001-12-27 US US10/033,571 patent/US7510875B2/en not_active Expired - Fee Related
-
2004
- 2004-07-30 US US10/909,066 patent/US7445930B2/en not_active Expired - Fee Related
-
2006
- 2006-08-23 US US11/508,780 patent/US20070155008A1/en not_active Abandoned
-
2007
- 2007-07-19 HK HK07107808.0A patent/HK1107116A1/en not_active IP Right Cessation
-
2009
- 2009-10-02 US US12/572,943 patent/US20100055763A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996027677A2 (en) * | 1995-03-07 | 1996-09-12 | Canji, Inc. | Method of purification of recombinant viral vectors containing a therapeutic gene |
Non-Patent Citations (3)
Title |
---|
BERG D. ET AL.: "High-level expression of secreted proteins from cells adapted to serum-free suspension culture", BIOTECHNIQUES, vol. 14, no. 6, June 1993 (1993-06-01), pages 972 - 978, XP002059902 * |
HUYGHE B G ET AL: "PURIFICATION OF A TYPE 5 RECOMBINANT ADENOVIRUS ENCODING HUMAN P53 BY COLUMN CHROMATOGRAPHY", HUMAN GENE THERAPY, vol. 6, no. 11, November 1995 (1995-11-01), pages 1403 - 1416, XP000611922 * |
PERRIN P ET AL: "An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system", VACCINE, vol. 13, no. 13, 1995, pages 1244-1250, XP004057477 * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1998022588A3 (en) | An improved method for the production and purification of adenoviral vectors | |
DK1135469T3 (en) | Improved method of production and purification of adenoviral vectors | |
Becerra et al. | Direct mapping of adeno-associated virus capsid proteins B and C: a possible ACG initiation codon. | |
DK0733103T3 (en) | Preparation of High Titers of Recombinant AAV Vectors | |
BR9913026A (en) | Process for purifying recombinant papillomavirus virus-like particles (vlps), and process for preparing a purified human papillomavirus vlp product suitable for use in a human vaccine | |
WO2001036615A3 (en) | Permanent amniocyte cell line, the production thereof and its use for producing gene transfer vectors | |
ATE278789T1 (en) | AUXILIARY FUNCTIONS FOR RECOMBINANT AAV VIRION PRODUCTION | |
EP1679368A1 (en) | Methods for purifying viruses | |
WO1998039463A3 (en) | Lentivirus based vector and vector system | |
EP1386967A3 (en) | DNA Encoding Mammalian phosphodiesterases | |
WO2000014205A3 (en) | Methods for generating high titer helper-free preparations of released recombinant aav vectors | |
AU5587198A (en) | Methods for preparing nucleotide integrases | |
WO1994013812A3 (en) | Novel entomopoxvirus genes, proteins and methods of use thereof | |
WO1998006827A3 (en) | Method for immortalizing cells | |
WO2000012741A3 (en) | Inducible expression system | |
CA2260765A1 (en) | Purified proteins, recombinant dna sequences and processes for controlling the ripening of coffee plants | |
Wahrmann et al. | Gene expression during the differentiation of myogenic cells of the L6 line | |
Donner et al. | Tyrosine aminotransferase from rat liver, a purification in three steps | |
AU5000797A (en) | High level of expression of ingap | |
Tsukagoshi et al. | Structure and Synthesis of a Lipid‐Containing Bacteriophage: An Endolysin Activity Associated with Bacteriophage PM2 | |
CA2289776A1 (en) | An infectious clone for human parainfluenza virus type 3 | |
WO1992014818A3 (en) | Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences | |
EP0884382A3 (en) | Processes for preparation of marek's disease virus using continuous mammalian cell lines | |
Bhatnagar et al. | Extracellular dextran sucrase from a new strain of Leuconostoc mesenteroides. | |
Kotiw et al. | Comparison of methods for the isolation and purification of infectious laryngotracheitis virus DNA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 97181254.3 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
CFP | Corrected version of a pamphlet front page |
Free format text: ADD INID NUMBER (63) "RELATED BY CONTINUATION (CON) OR CONTINUATION-IN-PART (CIP) TO EARLIER APPLICATION" WHICH WAS INADVERTENTLY OMITTED FROM THE FRONT PAGE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i | ||
COP | Corrected version of pamphlet |
Free format text: PAGES 1/32-32/32, DRAWINGS, REPLACED BY NEW PAGES 1/44-44/44; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
ENP | Entry into the national phase |
Ref document number: 2272820 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1998 523965 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019997004446 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 335947 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997950677 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 53617/98 Country of ref document: AU |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1997950677 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1019997004446 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 53617/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1019997004446 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 1997950677 Country of ref document: EP |